Principal investigator Lewis Romer, MD, of Johns Hopkins Medicine joined us to discuss the actively-recruiting MoD PAH trial assessing mono vs dual therapy for pediatric PAH. Lewis Romer, MD, ...
Neffy was first approved in September 2024 to treat type 1 allergic reactions in patients who weigh at least 66 lbs (33 kg). ARS Pharmaceuticals has announced new developments for neffy (epinephrine ...
The REACH Institute awards 50 cognitive behavioral therapy (CBT) scholarships to primary care clinicians nationwide to bridge critical gaps in pediatric mental health care ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback